Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

783.12 +3.46 (+0.44%)
Streaming Delayed Price Updated: 10:35 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
49 50 Next >
News headline image
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure ↗
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
News headline image
These S&P500 stocks are moving in today's pre-market session ↗
Pre-market stock analysis of S&P500 stocks on 2025-05-30: top gainers and losers in today's session. 
Via Chartmill
News headline image
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal. 
Via Benzinga
News headline image
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment ↗
Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes. 
Via Stocktwits
Topics Government Stocks
News headline image
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
News headline image
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. ↗
Via The Motley Fool
Topics Artificial Intelligence Bankruptcy
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Value Stocks with Questionable Fundamentals
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Does the 23andMe Acquisition Make Regeneron a Buy Now? ↗
Via The Motley Fool
Topics Bankruptcy
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
3 Cash-Producing Stocks in Hot Water
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
What's going on in today's session: S&P500 movers ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal ↗
Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025. 
Via Benzinga
News headline image
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts ↗
Upon closing of the deal, 23andMe will be operated as a wholly owned direct or indirect unit of Regeneron and will continue operations as a personal genomics service. 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
News headline image
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction ↗
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank. 
Via Investor's Business Daily
Topics Bankruptcy
News headline image
3 Stocks That Will Profit From Trump's Drug Price Cut ↗
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
News headline image
1 Nasdaq 100 Stock with Exciting Potential and 2 to Think Twice About
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that... 
Via StockStory
News headline image
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential. 
Via MarketBeat
Topics Government World Trade
News headline image
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
News headline image
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
News headline image
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
Best Biotech Stocks to Buy in 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. 
Via MarketBeat
Topics ETFs Economy Government
News headline image
REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3%... 
Via StockStory
News headline image
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
News headline image
3 of Wall Street’s Favorite Stocks Skating on Thin Ice
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 to Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.